Sitemap - 2024 - Big Pharma Sharma
ASH Part 2: Anito-cel is off to the races, but will it be fast enough to catch-up to Cilta-cel?
ASH 2024 | Part 1: Miltenyi and Galapagos Aim Big in CAR-T, but Gaps Remain
Two things I think coming out of SITC 2024
Priority Review Voucher (PRV) Market Update – Big Pharma Unloading its Ammo
TIGIT: Too Legit to Quit? Or Just Can't Hit?
Three Major Implications Coming out of ESMO 2024
What the Ivonescimab Data at WCLC Tells Us About China's Role in Drug Development
Two charts that highlight the future of GLP-1s after Diabetes and Obesity
Rethinking the FDA, Innovation, and the Regulatory State: Parsing Vivek and Balaji’s Vision
Why You Should Be Paying Attention to the Emerging IgAN Market
ESMO 2024: My Most Interesting Abstracts
What the Artiva IPO says about the state of cell therapy for autoimmune disease
Safety signals in Lyell’s ROR-1 CAR-T data put key strategic decisions in focus
Can Roche’s COLUMVI threaten the CAR-T renaissance in DLBCL?
ASCO 2024 Temperature Check - Part 2
ASCO 2024 Temperature Check – Part One
Mini ASCO 2024 Preview: An Emerging Battle in Frontline Melanoma
The Renaissance of Psychedelics: Charting New Paths in Mental Health Treatment
ASCO 2024: Most Interesting Data Upcoming at the Conference
CD19 Bispecifics: The Harbinger of Challenges for Autoimmune CAR-T Therapies
Some signs of life for new IL-2 variants
Deconstructing GRANITE's Downfall: Perils for the Neoantigen Vaccine Field?
Bayer's Renaissance: A Roadmap for Revival
What the BCMA CAR-T Adcom Revealed About the Field's Future
AACR 2024 Most Interesting Abstract Titles
Updated Cell Therapy Autoimmune Landscape
A TIL-ing Odyssey Finally Ends in Approval for Iovance's AMTAGVI
An Interview with AI About Its Role in Drug Development
A Few Charts that Outline the Dearth of Innovation in TCR-T Cell Therapies
Big Pharma Sharma's Bullets: (Over)reacting to Recent Industry News
The Next Phase: How BioNTech and Moderna Are Positioning For Their Post-COVID Eras
On the Ground at JPM: Key Themes that Could Define Big Pharma Companies in 2024
AstraZeneca’s build towards becoming an immune cell therapy leader